Details

Project TitleFecal Neopterin Concentration Measurement as an Indicator of Disease Activity in Crohn's Disease or Ulcerative Colitis
Track Code2011-025
Short Description

Identification of a new biomarker for inflammatory bowel disease (IBD).

#diagnositics #helathcare #diagnostictool #gastroenterology

Abstract

A Northwestern researcher has identified a new biomarker for inflammatory bowel disease (IBD). His study reveals that individuals with Crohn's disease and ulcerative colitis have increased levels of fecal neopterin, a metabolite of cyclic guanosine monophosphate, which is released by activated T-lymphocytes and macrophages following induction by -interferon. Further, he has determined that IBD severity also significantly correlates with the level of fecal neopterin. Among Crohn's disease patients, fecal neopterin was higher in those with either clinically active or inactive disease than in healthy subjects. For ulcerative colitis patients, fecal neopterin concentration was higher in those with active disease than in those with inactive disease or healthy controls. Neither serum nor urine neopterin concentrations were increased in patients with active IBD.

 
TagsDIAGNOSTICS: detection, gastroenterology, HEALTHCARE: Diagnostic Tool
 
Posted DateJan 31, 2012 2:21 PM

Inventor(s)

Alan Buchman

Applications

  • Diagnosis of inflammatory bowel diseases
    • Crohn's disease
    • Ulcerative colitis

Advantages

  • Fecal Detection of biomarkers
  • Non-invasive

IP Status

A patent application has been filed.

Contact Information

Michael Moore, PhD
Invention Manager
(p) (847) 491-4645

(e) michaelmoore@northwestern.edu